US Stock MarketDetailed Quotes
CLNN Clene
- 4.1800
- +0.0300+0.72%
Close Nov 29 13:00 ET
- 4.2200
- +0.0400+0.96%
Post 17:01 ET
33.36MMarket Cap-790P/E (TTM)
4.5300High4.0900Low106.15KVolume4.2000Open4.1500Pre Close450.19KTurnover2.62%Turnover RatioLossP/E (Static)7.98MShares12.000052wk High-8.09P/B16.95MFloat Cap3.818152wk Low--Dividend TTM4.06MShs Float356.4000Historical High--Div YieldTTM10.60%Amplitude3.8180Historical Low4.2410Avg Price1Lot Size
About Clene Company
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.
Company Profile
SymbolCLNN
Company NameClene
Listing DateAug 27, 2018
Founded2013
CEOMr. Robert Etherington
MarketNASDAQ
Employees85
Fiscal Year Ends12-31
Address6550 South Millrock Drive,Suite G50
CitySalt Lake City
ProvinceUtah
CountryUnited States of America
Zip Code84121
Phone1-801-676-9695
Websitehttp://www.clene.com
Company Executives
- Name
- Position
- Salary
- Robert Etherington
- President, Chief Executive Officer and Director
- 1.71M
- Morgan R. Brown
- Chief Financial Officer and Principal Accounting Officer
- 993.70K
- Mark Mortenson
- Chief Science Officer
- 1.38M
- David J. Matlin
- Chairman of the Board
- 139.93K
- Jonathon T. Gay
- Independent Director
- 96.13K
- Dr. Vallerie V. McLaughlin, M.D.
- Independent Director
- 106.84K
- Professor Matthew Kiernan, PhD
- Independent Director
- --
- Shalom Jacobovitz
- Independent Director
- 121.93K
- Dr. Arjun JJ Desai, M.D.
- Independent Director
- --
- Alison H. Mosca
- Independent Director
- 123.39K
- Reed Neil Wilcox
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data